Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00453609
Status:
COMPLETED
Last Update Posted:
2008-12-11
First Post:
2007-03-27
Brief Title:
Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness SMI
Sponsor:
State University of New York - Upstate Medical University
Organization:
State University of New York - Upstate Medical University
Study Overview
Official Title:
Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness SMI An Open Prospective Pilot Trial
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
vivitrol
Brief Summary:
The overall goal of this project is to improve the treatment of alcohol dependence in patients with serious mental illness SMI SMI for this study is defined as any patient with any of the following diagnoses schizophrenia schizoaffective disorder and bipolar type I or type II disorder Alcohol and other substance use disorders SUDs are common among individuals with SMI SUD comorbidity is associated with many adverse consequences However to date few reports have addressed the efficacy of pharmacological treatments for SUDs in this population Naltrexone pharmacotherapy is an effective treatment for alcohol dependence but it has not been systematically applied to the care of patients with SMI The primary aim of this study is to determine the feasibility of long-acting injectable naltrexone administration in a clinical trial in patients with SMI who also have a diagnosis of alcohol dependence Secondary aims include providing a preliminary assessment of the tolerability and safety of long-acting injectable naltrexone in patients with SMI who also have a diagnosis of alcohol dependence An additional aim is to provide a preliminary assessment of the efficacy of long-acting injectable naltrexone in reducing alcohol use from baseline levels
Detailed Description:
The proposed project is a 1-year pilot program of research which will examine the feasibility of a new intramuscular IM long-acting form of naltrexone The long-acting form of naltrexone may improve medication adherence which has been shown to be critical to successful naltrexone treatment of alcohol dependence The study is a 16-week randomized prospective open-label trial including a 12-week course of monthly naltrexone injections A follow-up interview will be conducted 4 weeks after discontinuation of medication Thirty subjects will be recruited Voucher-based incentives will be provided to all subjects to ensure attendance for medication administration Weekly motivational counseling sessions will be conducted and will focus on improving motivation to stop alcohol use Study outcomes consist of self-report and biological measures of alcohol use measures of psychiatric symptom severity and neurocognitive functioning and genetic testing to examine functional polymorphism Asn40Asp differences in the subjects μ-opioid receptors OPRM1 which may predict response to naltrexone treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None